Department of Child Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Department of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Pan Afr Med J. 2023 Nov 9;46:78. doi: 10.11604/pamj.2023.46.78.32240. eCollection 2023.
Spinal muscular atrophy (SMA) is an autosomal recessive inherited motor neuron disease characterized by progressive muscle weakness due to degeneration and loss of the anterior horn cells in the spinal cord and the brain stem nuclei from foetal life through infancy and childhood. SMA is prevalent in Ghanaian children, though not widely reported. Cases are likely missed or misdiagnosed due to lack of expertise and investigations. Newborn screening is not currently available in Ghana. The management remains supportive as newly approved genetic modifications therapies are currently not available. We present a retrospective folder review of children attending a tertiary pediatric neurology clinic who were diagnosed with SMA and confirmed by molecular genetic testing. Between January 2018 and August 2021, five (5) children from three families had molecular genetic tests confirming their diagnosis of SMA. Three (3) children had SMA I phenotype while 2 had SMA III phenotype. Two (2) of the 3 children with SMA I died from respiratory complications. The last surviving child with SMA I was diagnosed through newborn screening program overseas and received gene modification therapy. Careful history and physical examination remain the best approach to diagnosis as confirmatory genetic testing and supplemental investigations are not readily available. The current management of the children with SMA in Ghana include respiratory care, physiotherapy, and genetic counselling. Genetic modification therapies are currently not available.
脊髓性肌萎缩症(SMA)是一种常染色体隐性遗传的运动神经元疾病,其特征是由于脊髓和脑干核的前角细胞退化和丧失,导致胎儿期至婴幼儿期进行性肌肉无力。SMA 在加纳儿童中较为常见,但并未广泛报道。由于缺乏专业知识和检查,病例可能被漏诊或误诊。加纳目前尚未开展新生儿筛查。由于新批准的基因修饰疗法目前不可用,因此治疗仍以支持性治疗为主。我们对在一家三级儿科神经科诊所就诊并通过分子遗传学检测确诊为 SMA 的儿童进行了回顾性文件夹审查。2018 年 1 月至 2021 年 8 月,来自三个家庭的五(5)名儿童进行了分子遗传学检测,证实了他们的 SMA 诊断。三(3)名儿童患有 SMA I 表型,2 名患有 SMA III 表型。3 名 SMA I 患儿中有 2 名因呼吸并发症死亡。最后一名存活的 SMA I 患儿是通过海外新生儿筛查计划诊断的,并接受了基因修饰治疗。仔细的病史和体格检查仍然是诊断的最佳方法,因为确认性基因检测和补充检查并不容易获得。目前加纳 SMA 患儿的治疗包括呼吸护理、物理治疗和遗传咨询。基因修饰疗法目前不可用。